Nonserious (grade < 2), nonhematologic adverse events affecting > 10% of subjects
| Adverse event . | No. (%) subjects affected . | No. (%) possibly related to treatment . |
|---|---|---|
| Constipation | 20 (55.6) | 14 (70) |
| Diarrhea | 17 (47.2) | 14 (82.4) |
| Injection site reaction | 14 (38.9) | 14 (100) |
| Pruritus | 10 (27.8) | 10 (100) |
| Rash/desquamation | 9 (25) | 9 (100) |
| Fatigue | 18 (50) | 13 (72.2) |
| Nausea | 9 (25) | 8 (88.9) |
| Dizziness | 9 (25) | 3 (33.3) |
| Fever (without neutropenia) | 5 (13.9) | 2 (40) |
| Insomnia | 6 (16.7) | 3 (50) |
| Dyspepsia | 4 (11.1) | 4 (100) |
| Headache | 5 (13.9) | 2 (40) |
| Cough | 8 (22.2) | 0 (0) |
| Dyspnea | 10 (27.8) | 4 (40) |
| Hypotension | 5 (13.9) | 2 (40) |
| Constitutional symptoms, other | 6 (16.7) | 4 (66.7) |
| Rigors/chills | 4 (11.1) | 1 (25) |
| Dermatology/skin, other | 9 (25) | 3 (33.3) |
| Anorexia | 6 (16.7) | 3 (50) |
| Gastrointestinal, other | 4 (11.1) | 1 (25) |
| Dysgeusia | 4 (11.1) | 4 (100) |
| Vomiting | 4 (11.1) | 3 (75) |
| Edema: limb | 5 (13.9) | 2 (40) |
| Adverse event . | No. (%) subjects affected . | No. (%) possibly related to treatment . |
|---|---|---|
| Constipation | 20 (55.6) | 14 (70) |
| Diarrhea | 17 (47.2) | 14 (82.4) |
| Injection site reaction | 14 (38.9) | 14 (100) |
| Pruritus | 10 (27.8) | 10 (100) |
| Rash/desquamation | 9 (25) | 9 (100) |
| Fatigue | 18 (50) | 13 (72.2) |
| Nausea | 9 (25) | 8 (88.9) |
| Dizziness | 9 (25) | 3 (33.3) |
| Fever (without neutropenia) | 5 (13.9) | 2 (40) |
| Insomnia | 6 (16.7) | 3 (50) |
| Dyspepsia | 4 (11.1) | 4 (100) |
| Headache | 5 (13.9) | 2 (40) |
| Cough | 8 (22.2) | 0 (0) |
| Dyspnea | 10 (27.8) | 4 (40) |
| Hypotension | 5 (13.9) | 2 (40) |
| Constitutional symptoms, other | 6 (16.7) | 4 (66.7) |
| Rigors/chills | 4 (11.1) | 1 (25) |
| Dermatology/skin, other | 9 (25) | 3 (33.3) |
| Anorexia | 6 (16.7) | 3 (50) |
| Gastrointestinal, other | 4 (11.1) | 1 (25) |
| Dysgeusia | 4 (11.1) | 4 (100) |
| Vomiting | 4 (11.1) | 3 (75) |
| Edema: limb | 5 (13.9) | 2 (40) |